Apoptin: Specific killer of tumor cells?

M. Tavassoli, L. Guelen, B. A. Luxon, J. Gäken

    Research output: Contribution to journalArticle

    45 Citations (Scopus)

    Abstract

    In the early 1990s it was discovered that the VP3/Apoptin protein encoded by the Chicken Anemia virus (CAV) possesses an inherent ability to specifically kill cancer cells. Apoptin was found to be located in the cytoplasm of normal cells while in tumor cells it was localized mainly in the nucleus. 1 These differences in the localization pattern were suggested to be the main mechanism by which normal cells show resistance to Apoptin-mediated cell killing. Although the mechanism of action of Apoptin is presently unknown, it seems to function by the induction of programmed cell death (PCD) after translocation from the cytoplasm to the nucleus and arresting the cell cycle at G 2/M, possibly by interfering with the cyclosome. 2 In addition, cancer specific phosphorylation of Threonine residue 108 has been suggested to be important for Apoptin's function to kill tumor cells. 3 In contrast to the large number of publications reporting that nuclear localization, induction of PCD and phosphorylation of Apoptin is restricted to cancer cells, several recent studies have shown that Apoptin has the ability to migrate to the nucleus and induce PCD in some of the normal cell lines tested. There is evidence that high protein expression levels as well as the cellular growth rate may influence Apoptin's ability to specifically kill tumor cells. Thus far both in vitro and in vivo studies indicate that Apoptin is a powerful apoptosis inducing protein with a promising prospective utility in cancer therapy. However, here we show that several recent findings contradict some of the earlier results on the tumor specificity of Apoptin, thus creating some controversy in the field. The aim of this article is to review the available data, some published and some unpublished, which either agree or contradict the reported "black and white" tumor cell specificity of Apoptin. Understanding what factors appear to influence its function should help to develop Apoptin into a potent anti-cancer agent.

    Original languageEnglish (US)
    Pages (from-to)717-724
    Number of pages8
    JournalApoptosis
    Volume10
    Issue number4
    DOIs
    StatePublished - Aug 2005

    Fingerprint

    Tumors
    Cells
    Neoplasms
    Cell death
    Phosphorylation
    Cell Death
    Cytoplasm
    Apoptosis Regulatory Proteins
    Threonine
    Viruses
    Proteins
    Publications
    Cell Cycle
    Cell Line
    Growth

    Keywords

    • Apoptin
    • Bcl10
    • CAV
    • Cyclosome
    • Cytoplasmic filaments
    • DEDAF
    • FADD
    • Hippi
    • NF-κB
    • NMR
    • Nuclear export
    • Nuclear localization
    • TAT-PTD
    • Tumor-specific apoptosis

    ASJC Scopus subject areas

    • Biochemistry, Genetics and Molecular Biology(all)
    • Cell Biology

    Cite this

    Tavassoli, M., Guelen, L., Luxon, B. A., & Gäken, J. (2005). Apoptin: Specific killer of tumor cells? Apoptosis, 10(4), 717-724. https://doi.org/10.1007/s10495-005-0930-3

    Apoptin : Specific killer of tumor cells? / Tavassoli, M.; Guelen, L.; Luxon, B. A.; Gäken, J.

    In: Apoptosis, Vol. 10, No. 4, 08.2005, p. 717-724.

    Research output: Contribution to journalArticle

    Tavassoli, M, Guelen, L, Luxon, BA & Gäken, J 2005, 'Apoptin: Specific killer of tumor cells?', Apoptosis, vol. 10, no. 4, pp. 717-724. https://doi.org/10.1007/s10495-005-0930-3
    Tavassoli M, Guelen L, Luxon BA, Gäken J. Apoptin: Specific killer of tumor cells? Apoptosis. 2005 Aug;10(4):717-724. https://doi.org/10.1007/s10495-005-0930-3
    Tavassoli, M. ; Guelen, L. ; Luxon, B. A. ; Gäken, J. / Apoptin : Specific killer of tumor cells?. In: Apoptosis. 2005 ; Vol. 10, No. 4. pp. 717-724.
    @article{f409d706b0844211ae272eed940aa826,
    title = "Apoptin: Specific killer of tumor cells?",
    abstract = "In the early 1990s it was discovered that the VP3/Apoptin protein encoded by the Chicken Anemia virus (CAV) possesses an inherent ability to specifically kill cancer cells. Apoptin was found to be located in the cytoplasm of normal cells while in tumor cells it was localized mainly in the nucleus. 1 These differences in the localization pattern were suggested to be the main mechanism by which normal cells show resistance to Apoptin-mediated cell killing. Although the mechanism of action of Apoptin is presently unknown, it seems to function by the induction of programmed cell death (PCD) after translocation from the cytoplasm to the nucleus and arresting the cell cycle at G 2/M, possibly by interfering with the cyclosome. 2 In addition, cancer specific phosphorylation of Threonine residue 108 has been suggested to be important for Apoptin's function to kill tumor cells. 3 In contrast to the large number of publications reporting that nuclear localization, induction of PCD and phosphorylation of Apoptin is restricted to cancer cells, several recent studies have shown that Apoptin has the ability to migrate to the nucleus and induce PCD in some of the normal cell lines tested. There is evidence that high protein expression levels as well as the cellular growth rate may influence Apoptin's ability to specifically kill tumor cells. Thus far both in vitro and in vivo studies indicate that Apoptin is a powerful apoptosis inducing protein with a promising prospective utility in cancer therapy. However, here we show that several recent findings contradict some of the earlier results on the tumor specificity of Apoptin, thus creating some controversy in the field. The aim of this article is to review the available data, some published and some unpublished, which either agree or contradict the reported {"}black and white{"} tumor cell specificity of Apoptin. Understanding what factors appear to influence its function should help to develop Apoptin into a potent anti-cancer agent.",
    keywords = "Apoptin, Bcl10, CAV, Cyclosome, Cytoplasmic filaments, DEDAF, FADD, Hippi, NF-κB, NMR, Nuclear export, Nuclear localization, TAT-PTD, Tumor-specific apoptosis",
    author = "M. Tavassoli and L. Guelen and Luxon, {B. A.} and J. G{\"a}ken",
    year = "2005",
    month = "8",
    doi = "10.1007/s10495-005-0930-3",
    language = "English (US)",
    volume = "10",
    pages = "717--724",
    journal = "Apoptosis : an international journal on programmed cell death",
    issn = "1360-8185",
    publisher = "Springer Netherlands",
    number = "4",

    }

    TY - JOUR

    T1 - Apoptin

    T2 - Specific killer of tumor cells?

    AU - Tavassoli, M.

    AU - Guelen, L.

    AU - Luxon, B. A.

    AU - Gäken, J.

    PY - 2005/8

    Y1 - 2005/8

    N2 - In the early 1990s it was discovered that the VP3/Apoptin protein encoded by the Chicken Anemia virus (CAV) possesses an inherent ability to specifically kill cancer cells. Apoptin was found to be located in the cytoplasm of normal cells while in tumor cells it was localized mainly in the nucleus. 1 These differences in the localization pattern were suggested to be the main mechanism by which normal cells show resistance to Apoptin-mediated cell killing. Although the mechanism of action of Apoptin is presently unknown, it seems to function by the induction of programmed cell death (PCD) after translocation from the cytoplasm to the nucleus and arresting the cell cycle at G 2/M, possibly by interfering with the cyclosome. 2 In addition, cancer specific phosphorylation of Threonine residue 108 has been suggested to be important for Apoptin's function to kill tumor cells. 3 In contrast to the large number of publications reporting that nuclear localization, induction of PCD and phosphorylation of Apoptin is restricted to cancer cells, several recent studies have shown that Apoptin has the ability to migrate to the nucleus and induce PCD in some of the normal cell lines tested. There is evidence that high protein expression levels as well as the cellular growth rate may influence Apoptin's ability to specifically kill tumor cells. Thus far both in vitro and in vivo studies indicate that Apoptin is a powerful apoptosis inducing protein with a promising prospective utility in cancer therapy. However, here we show that several recent findings contradict some of the earlier results on the tumor specificity of Apoptin, thus creating some controversy in the field. The aim of this article is to review the available data, some published and some unpublished, which either agree or contradict the reported "black and white" tumor cell specificity of Apoptin. Understanding what factors appear to influence its function should help to develop Apoptin into a potent anti-cancer agent.

    AB - In the early 1990s it was discovered that the VP3/Apoptin protein encoded by the Chicken Anemia virus (CAV) possesses an inherent ability to specifically kill cancer cells. Apoptin was found to be located in the cytoplasm of normal cells while in tumor cells it was localized mainly in the nucleus. 1 These differences in the localization pattern were suggested to be the main mechanism by which normal cells show resistance to Apoptin-mediated cell killing. Although the mechanism of action of Apoptin is presently unknown, it seems to function by the induction of programmed cell death (PCD) after translocation from the cytoplasm to the nucleus and arresting the cell cycle at G 2/M, possibly by interfering with the cyclosome. 2 In addition, cancer specific phosphorylation of Threonine residue 108 has been suggested to be important for Apoptin's function to kill tumor cells. 3 In contrast to the large number of publications reporting that nuclear localization, induction of PCD and phosphorylation of Apoptin is restricted to cancer cells, several recent studies have shown that Apoptin has the ability to migrate to the nucleus and induce PCD in some of the normal cell lines tested. There is evidence that high protein expression levels as well as the cellular growth rate may influence Apoptin's ability to specifically kill tumor cells. Thus far both in vitro and in vivo studies indicate that Apoptin is a powerful apoptosis inducing protein with a promising prospective utility in cancer therapy. However, here we show that several recent findings contradict some of the earlier results on the tumor specificity of Apoptin, thus creating some controversy in the field. The aim of this article is to review the available data, some published and some unpublished, which either agree or contradict the reported "black and white" tumor cell specificity of Apoptin. Understanding what factors appear to influence its function should help to develop Apoptin into a potent anti-cancer agent.

    KW - Apoptin

    KW - Bcl10

    KW - CAV

    KW - Cyclosome

    KW - Cytoplasmic filaments

    KW - DEDAF

    KW - FADD

    KW - Hippi

    KW - NF-κB

    KW - NMR

    KW - Nuclear export

    KW - Nuclear localization

    KW - TAT-PTD

    KW - Tumor-specific apoptosis

    UR - http://www.scopus.com/inward/record.url?scp=23944504820&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=23944504820&partnerID=8YFLogxK

    U2 - 10.1007/s10495-005-0930-3

    DO - 10.1007/s10495-005-0930-3

    M3 - Article

    C2 - 16133863

    AN - SCOPUS:23944504820

    VL - 10

    SP - 717

    EP - 724

    JO - Apoptosis : an international journal on programmed cell death

    JF - Apoptosis : an international journal on programmed cell death

    SN - 1360-8185

    IS - 4

    ER -